Clinical Social Workers in Gretna, NE Accepting Medicare

3 Clinical Social Workers found. Showing 1 - 3

Ayla Wilhite, PLMHP, PCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 916 Village Sq, Gretna, NE 68028 Phone: 402-302-0211

Ashley Whitley, PLMHP Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 11722 Willow Park Dr, Gretna, NE 68028 Phone: 402-759-1789

Mrs. Sarah Abegglen, LCSW/LIMHP Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 19820 Sherwood Cir, Gretna, NE 68028 Phone: 308-708-0603

News Archive

Bone marrow and stem cell transplantation rejection averted by UV light exposure

One of the unfortunate side effects of bone marrow and stem cell transplantation is that the newly implanted cells often stage an internal attack against the patient they're intended to help.

First study to describe transporter system that bacteria use to ensure their survival

Bacteria responsible for middle ear infections, pink eye and sinusitis protect themselves from further immune attack by transporting molecules meant to destroy them away from their inner membrane target, according to a study from Nationwide Children's Hospital.

Researchers identify key protein involved in irregular brain cell activity

In a new study in mice, researchers have identified a key protein involved in the irregular brain cell activity seen in autism spectrum disorders and epilepsy. The protein, p53, is well-known in cancer biology as a tumor suppressor.

New anti-HIV medication etravirine shows great promise

The AIDS Institute, a national public policy research, advocacy, and education organization, is encouraged with the FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade.

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

Read more Medical News

› Verified 3 days ago